NASDAQ:FATE - Fate Therapeutics Stock Price, Forecast & News

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics Inc (NASDAQ:FATE) posted its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The biopharmaceutical company had revenue of $2.43 million for the quarter, compared to analysts' expectations of $1.75 million. Fate Therapeutics had a negative return on equity of 48.94% and a negative net margin of 900.24%. The firm's quarterly revenue was up 136.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.31) EPS. View Fate Therapeutics' Earnings History.

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Fate Therapeutics.

16 equities research analysts have issued 1-year price targets for Fate Therapeutics' shares. Their forecasts range from $20.00 to $34.00. On average, they anticipate Fate Therapeutics' stock price to reach $26.63 in the next twelve months. This suggests that the stock has a possible downside of 13.9%. View Analyst Price Targets for Fate Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

News headlines about FATE stock have trended very positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fate Therapeutics earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Rigel Pharmaceuticals (RIGL), Amarin (AMRN), Immunomedics (IMMU) and Exelixis (EXEL).

Fate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (9.11%), Victory Capital Management Inc. (5.59%), Victory Capital Management Inc. (4.53%), State Street Corp (3.15%), Franklin Resources Inc. (2.33%) and Jennison Associates LLC (1.73%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Point72 Asset Management L.P., State Street Corp, Victory Capital Management Inc., First Trust Advisors LP, UBS Group AG, Rafferty Asset Management LLC and Citigroup Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.

FATE stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., EcoR1 Capital LLC, Marshall Wace North America L.P., Sofinnova Investments Inc., Goldman Sachs Group Inc., Pictet Asset Management Ltd., Schroder Investment Management Group and ARK Investment Management LLC. View Insider Buying and Selling for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $30.94.

Fate Therapeutics has a market capitalization of $2.34 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]